BarbaraJoySniderMD

Dementia & Geriatrics

Professor of Neurology, Memory and Aging Division of Adult Neurology - Washington University St. Louis

Dr. Snider is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
4488 Forest Park Ave
Ste 160
Saint Louis, MO 63108
Phone+1 314-362-1408

Fax+1 314-286-1985

Dr. B. Joy Snider is a neurologist in Saint Louis, MO and is affiliated with Barnes-Jewish Hospital. She received her medical and graduate degrees (PhD in Biochemistry) from University of Texas Southwestern Medical School and has been in practice 28 years. She specializes in dementia & geriatrics and is experienced in Alzheimer disease and behavioral neurology / neuropsychiatry. She leads the Knight ADRC Clinical Trials Unit and serves as the Medical Director for the faculty dementia specialty practice, the Memory Diagnostic Center. She has served as the Adult Neurology Residency Program Director since 2009.

University of Texas Southwestern Medical CenterResidency, Neurology, 1990 - 1993
Texas Health Resources (Dallas)Internship, Internal Medicine, 1989 - 1990
University of Texas Southwestern Medical SchoolClass of 1989

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

PubMed

212 citations
Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
Martin R. Farlow, Steven E. Arnold, Christopher H. van Dyck, Paul S. Aisen, B. Joy Snider
Alzheimer's & Dementia. 2012-07-01
32 citations
Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network.
Aurélie Bussy, B. Joy Snider, Dean W. Coble, Chengjie Xiong, Anne M. Fagan
Neurobiology of Aging. 2019-03-01
190 citations
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Stephen Salloway, Martin R. Farlow, Eric McDade, David B. Clifford, Guoqiao Wang
Nature Medicine. 2021-06-21

Podcast: Newly Approved Drug May Slow Progression of Alzheimer’sAugust 6th, 2023
What to Know About the New Alzheimer’s Drug Leqembi – Washington University School of Medicine in St. LouisAugust 18th, 2023

Neuroprotective Effects Of Enhanced Proteasome FunctionNational Institute Of Neurological Disorders And Stroke2004–2006
Neuroprotective Effect Of Heat Stress In Cortical NeuronNational Institute Of Neurological Disorders And Stroke1995–1999